Last reviewed · How we verify
Bavarian Nordic smallpox vaccine
At a glance
| Generic name | Bavarian Nordic smallpox vaccine |
|---|---|
| Also known as | Imvamune |
| Sponsor | McMaster University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (PHASE2)
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC (PHASE4)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo (PHASE2)
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections (PHASE2)
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells (PHASE2)
- Evaluating the Human Immune Response to the JYNNEOS Vaccine (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bavarian Nordic smallpox vaccine CI brief — competitive landscape report
- Bavarian Nordic smallpox vaccine updates RSS · CI watch RSS
- McMaster University portfolio CI